Riociguat
- Generic Name
- Riociguat
- Brand Names
- Adempas
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN8O2
- CAS Number
- 625115-55-1
- Unique Ingredient Identifier
- RU3FE2Y4XI
- Background
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pul...
- Indication
Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
...
- Associated Conditions
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Mark Gladwin
- Target Recruit Count
- 130
- Registration Number
- NCT02633397
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
🇺🇸UPMC Division of Hematology and Oncology, Pittsburgh, Pennsylvania, United States
Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 105
- Registration Number
- NCT02634203
- Locations
- 🇫🇷
AP-HP, Bicêtre Hospital, Le Kremlin Bicetre, France
Riociguat for Sarcoidosis Associated Pulmonary Hypertension
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT02625558
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Richard Moon
- Target Recruit Count
- 28
- Registration Number
- NCT02024386
- Locations
- 🇺🇸
Duke Center for Hyperbaric Medicine and Environmental Physiology, Trent Drive, Building CR2, Room 0584, Box 3823,, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.